ERYTECH Pharma develops ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs.
Its first product reported positive Phase III results of its pivotal study in Acute Lymphoblastic Leukemia (ALL) in Europe and is in four other clinical programs : a Phase IIb study in Acute Myeloid Leukemia (AML) , a Phase II study in pancreatic cancer and an Expanded Access program in ALL in Europe, and a Phase I/II study in ALL in the USA.
ERYTECH proprietary technology is based on encapsulation of therapeutic compounds into red blood cells.
The company has a production unit located in Lyon with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements, one with Orphan Europe (Recordati) and one with Teva.
ERYTECH Pharma announced today that it received Deloitte Technology Fast 50 award in the “Promising Biotech” category for France’s Grand Rhone-Alpes region.
ERYTECH Pharma announces the upcoming presentation of three abstracts at the American Society of Hematology (ASH) Annual Meeting taking place in Orlando, Florida, USA from December 5-8, 2015.
ERYTECH Pharma reports cash balance and revenues for the third quarter of 2015.
ERYTECH Pharma announces the publication of two peer-reviewed manuscripts describing clinical results obtained with ERY-ASP/GRASPA®.
ERYTECH pharma attends Qualified Person Forum 2015 from November 24-26 in Berlin, Germany.
ERYTECH Pharma takes part in ESMO Symposium Immuno-Oncology 2015 on November 20-21, 2015, in Lausanne, Switzerland.
FINANCE – ERYTECH attends Actionaria at Palais des congrès, Paris (booth C20 Hall Maillot niv.2) on November 20 and 21st, 2015.
FINANCE – ERYTECH attends Jefferies 2015 Global Healthcare Conference in London from November 18 to 19, 2015.